Insmed | INSM - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Cytokinetics USD 200.58M 4.46M 2026-03
DBV Technologies USD 37.05M 4.06M 2025-09
Gilead Sciences USD 23.52B 18.55B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 506.24M 7.31M 2026-03
Novartis USD 9.8B 23M 2025-12
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03